ARTICLE | Clinical News
IMC-C225 monoclonal antibody against epidermal growth factor regulatory update
February 5, 2001 8:00 AM UTC
The FDA granted fast track designation for IMC-C225 to treat refractory colorectal carcinoma. IMC-C225 is in Phase III testing in combination with radiotherapy and chemotherapy to treat advanced head ...